Tiziana Life Sciences (NASDAQ:TLSA) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Tiziana Life Sciences to “strong sell” from “sell.” However, ratings from other firms range from buy to sell, resulting in a consensus “hold” rating.
• TLSA opened at $1.12, with shares down 1.8%; the stock has traded between $0.76 and $2.33 over the past year.
• CEO Ivor Elrifi purchased 667,000 shares in August, and insiders have acquired 988,423 shares worth about $986,000 over the past 90 days. Tiziana is developing foralumab, an antibody candidate targeting neuroinflammatory and autoimmune diseases.

Tiziana Life Sciences (NASDAQ:TLSA - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

A number of other research firms have also issued reports on TLSA. Weiss Ratings reiterated a "sell (e+)" rating on shares of Tiziana Life Sciences in a research note on Wednesday, August 26th. Zacks Research upgraded shares of Tiziana Life Sciences to a "hold" rating in a research note on Tuesday, July 14th. Finally, BTIG Research restated a "buy" rating on shares of Tiziana Life Sciences in a research report on Tuesday, September 22nd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold".

Tiziana Life Sciences Stock Down 1.8%

TLSA opened at $1.12 on Friday. The business has a 50-day moving average of $1.01 and a 200-day moving average of $1.18. Tiziana Life Sciences has a fifty-two week low of $0.76 and a fifty-two week high of $2.33.

Insider Transactions at Tiziana Life Sciences

In other Tiziana Life Sciences news, CEO Ivor Elrifi bought 667,000 shares of the business's stock in a transaction on Monday, August 3rd. The shares were bought at an average cost of $1.00 per share, for a total transaction of $667,000.00. Following the transaction, the chief executive officer owned 4,472,261 shares in the company, valued at approximately $4,472,261. This trade represents a 17.53% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders acquired 988,423 shares of company stock worth $985,909. 39.82% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tiziana Life Sciences

A hedge fund recently bought a new position in Tiziana Life Sciences stock. Mid American Wealth Advisory Group Inc. acquired a new position in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 323,240 shares of the company's stock, valued at approximately $414,000. Mid American Wealth Advisory Group Inc. owned 0.25% of Tiziana Life Sciences as of its most recent SEC filing.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd. NASDAQ: TLSA is a clinical-stage biotechnology company developing therapeutics for neuroinflammatory and autoimmune diseases. The company's lead product candidate is foralumab, a fully human monoclonal antibody that targets the CD3 receptor on T cells and is being developed in an intranasal formulation designed to modulate immune activity.

Tiziana has evaluated foralumab in clinical research involving non-active secondary progressive multiple sclerosis and has also investigated its potential in conditions involving neuroinflammation, including Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.